{"DataElement":{"publicId":"2227071","version":"1","preferredName":"Oral Antiandrogen Therapy Agent Administered Name","preferredDefinition":"the name of the oral antiandrogen agent administered.","longName":"OR_AN_AGT_ADM_NAME","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2227069","version":"1","preferredName":"Oral Antiandrogen Therapy Agent Administered","preferredDefinition":"information related to the oral antiandrogen agent administered.","longName":"ORAL_ANTIAND_AGT_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2227067","version":"1","preferredName":"Oral Antiandrogen Therapy Agent","preferredDefinition":"Oral; of, or relating to, or affecting, or for use in the mouth.:Treatment with drugs used to block production or interfere with the action of male sex hormones.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C25311:C15481:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral","conceptCode":"C25311","definition":"Of, or relating to, or affecting, or for use in the mouth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Antiandrogen Therapy","conceptCode":"C15481","definition":"A therapeutic regimen that utilizes pharmaceuticals to reduce serum levels of male sex hormones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6C1590C-7730-60E6-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-10","modifiedBy":"ONEDATA","dateModified":"2005-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6C1590C-7733-60E6-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2227070","version":"1","preferredName":"Antiandrogen Therapy Agent Name","preferredDefinition":"the name of the antiandrogen agent.","longName":"ANTIADRO_AGT_NAME","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":"5","maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6C1590C-776A-60E6-E034-0003BA3F9857","beginDate":"2005-05-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-10","modifiedBy":"CAMPBELB","dateModified":"2005-05-10","deletedIndicator":"No"},{"value":"Not started","valueDescription":"Not started","ValueMeaning":{"publicId":"2574747","version":"1","preferredName":"Not started","longName":"2574747","preferredDefinition":"Not started","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F108-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-10","modifiedBy":"CAMPBELB","dateModified":"2005-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6C298B7-18A2-1BA2-E034-0003BA3F9857","beginDate":"2005-05-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-10","modifiedBy":"ONEDATA","dateModified":"2005-05-10","deletedIndicator":"No"},{"value":"Casodex","valueDescription":"CASODEX","ValueMeaning":{"publicId":"2561413","version":"1","preferredName":"CASODEX","longName":"2561413","preferredDefinition":"CASODEX","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Casodex","conceptCode":"C0591237","definition":"Definition not available.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BCF2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-02","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6C298B7-18A4-1BA2-E034-0003BA3F9857","beginDate":"2005-05-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-10","modifiedBy":"ONEDATA","dateModified":"2005-05-10","deletedIndicator":"No"},{"value":"Eulexin","valueDescription":"Eulexin","ValueMeaning":{"publicId":"2574748","version":"1","preferredName":"Eulexin","longName":"2574748","preferredDefinition":"Eulexin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F109-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-10","modifiedBy":"CAMPBELB","dateModified":"2005-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6C298B7-18A8-1BA2-E034-0003BA3F9857","beginDate":"2005-05-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-10","modifiedBy":"ONEDATA","dateModified":"2005-05-10","deletedIndicator":"No"},{"value":"Not taken","valueDescription":"Not taken","ValueMeaning":{"publicId":"2571951","version":"1","preferredName":"Not taken","longName":"2571951","preferredDefinition":"Not taken","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E61C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-09-17","modifiedBy":"SHIDED","dateModified":"2004-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1EEA8BE5-3800-2059-E044-0003BA3F9857","beginDate":"2006-10-03","endDate":null,"createdBy":"PWEST","dateCreated":"2006-10-03","modifiedBy":"ONEDATA","dateModified":"2006-10-03","deletedIndicator":"No"},{"value":"Nilutamide (Nilandron)","valueDescription":"Nilutamide","ValueMeaning":{"publicId":"2573402","version":"1","preferredName":"Nilutamide","longName":"2573402","preferredDefinition":"A drug that blocks the effects of male hormones in the body. It is a type of antiandrogen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilutamide","conceptCode":"C1173","definition":"A synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent growth of normal and neoplastic prostate cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBC7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1EEB7A6C-E9A7-205B-E044-0003BA3F9857","beginDate":"2006-10-03","endDate":null,"createdBy":"PWEST","dateCreated":"2006-10-03","modifiedBy":"PWEST","dateModified":"2006-11-15","deletedIndicator":"No"},{"value":"Flutamide (Eulexin)","valueDescription":"FLUTAMIDE","ValueMeaning":{"publicId":"2561412","version":"1","preferredName":"FLUTAMIDE","longName":"2561412","preferredDefinition":"FLUTAMIDE","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flutamide","conceptCode":"C509","definition":"A toluidine derivative and a nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BCF1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-02","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1EEB7A6C-E9B8-205B-E044-0003BA3F9857","beginDate":"2006-10-03","endDate":null,"createdBy":"PWEST","dateCreated":"2006-10-03","modifiedBy":"ONEDATA","dateModified":"2006-10-03","deletedIndicator":"No"},{"value":"Bicalutamide (Casodex)","valueDescription":"Bicalutamide","ValueMeaning":{"publicId":"2573403","version":"1","preferredName":"Bicalutamide","longName":"2573403","preferredDefinition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bicalutamide","conceptCode":"C1599","definition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBC8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1EEB7A6C-E9C9-205B-E044-0003BA3F9857","beginDate":"2006-10-03","endDate":null,"createdBy":"PWEST","dateCreated":"2006-10-03","modifiedBy":"ONEDATA","dateModified":"2006-10-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184314","version":"1","preferredName":"Name","preferredDefinition":"A language unit by which a person or thing is known.","longName":"Name","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Person Name","conceptCode":"C25191","definition":"A word or group of words indicating the identity of a person usually consisting of a first (personal) name and a last (family) name with an optional middle name. In some cultural traditions the family name comes first.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1E12-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6C1590C-7753-60E6-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-10","modifiedBy":"MAESKEB","dateModified":"2009-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811835","version":"1","longName":"Melanoma","context":"CTEP"},{"publicId":"2811871","version":"1","longName":"Colorectal","context":"CTEP"},{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"},{"publicId":"2811908","version":"1","longName":"Gynecologic","context":"CTEP"},{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"},{"publicId":"2811950","version":"1","longName":"Multiple Myeloma","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4171065","version":"1","longName":"RTOG-0924","context":"NRG"},{"publicId":"4171063","version":"1","longName":"RTOG-0534","context":"NRG"},{"publicId":"4171064","version":"1","longName":"RTOG-0815","context":"NRG"}]}],"AlternateNames":[{"name":"OR_AN_AGT_ADM_NAME","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Oral antiandrogen taken","type":"Preferred Question Text","description":"Oral antiandrogen taken","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Oral antiandrogen therapy","url":null,"context":"CTEP"}],"origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"F6C2B711-C57B-1B9C-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-10","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}